Keveyis Approval History
FDA Approved: Yes (First approved August 7, 2015)
Brand name: Keveyis
Generic name: dichlorphenamide
Dosage form: Tablets
Company: Taro Pharmaceutical Industries Ltd.
Treatment for: Primary Hyperkalemic and Hypokalemic Periodic Paralysis
Keveyis (dichlorphenamide) is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis.
Development History and FDA Approval Process for Keveyis
|Aug 10, 2015||FDA Approves Keveyis (dichlorphenamide) for Primary Hyperkalemic and Hypokalemic Periodic Paralysis|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.